Drug product revenue from commercial-grade active pharmaceutical ingredient (“API”) or bulk drug product sales to Astellas and AstraZeneca was as follows for the three and nine months ended September 30, 2025 and 2024 (in thousands):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025		2024
Astellas Japan Agreement	$	(378	)	$	(1,355	)	$	1,446	$	(3,926	)
Astellas Europe Agreement		1,335			1,093			3,321		3,209
AstraZeneca U.S./RoW Agreement		—			—			—		25,671
Drug product revenue, net	$	957		$	(262	)	$	4,767	$	24,954

Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):


	Balance at December 31, 2024			Recognized as Revenue		Reclassified to Accrued Liability / Accounts Payable		Balance at September 30, 2025
Drug product revenue - deferred revenue:
Astellas Europe Agreement	$	(9,901	)	$	3,321	$	903	$	(5,677	)

Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the related deferred revenue that was considered as a contract liability that was not included in the disposal group held for sale as of December 31, 2024 (in thousands):


	Balance at December 31, 2024			Additions			Recognized as Revenue (Discontinued Operations)		Currency Translation and Other			Balance at September 30, 2025
AstraZeneca China performance obligation - deferred revenue	$	(132,097	)	$	(82,494	)	$	218,575	$	(3,984	)	$	—

The related net product revenue recognized from the sales to Falikang was $165.3 million and $42.2 million for the three months ended September 30, 2025 and 2024, and $218.6 million and $115.3 million for the nine months ended September 30, 2025 and 2024, respectively, which were included in the discontinued operations in the condensed consolidated statements of operations together with the sales directly to distributors.